The latest price target for Anavex Life Sciences (NASDAQ:AVXL) was reported by HC Wainwright & Co. on December 26, 2024. The analyst firm set a price target for $42.00 expecting AVXL to rise to within 12 months (a possible 218.18% upside). 14 analyst firms have reported ratings in the last year.

The latest analyst rating for Anavex Life Sciences (NASDAQ:AVXL) was provided by HC Wainwright & Co., and Anavex Life Sciences maintained their buy rating.

There is no last upgrade for Anavex Life Sciences

The last downgrade for Anavex Life Sciences Corp happened on December 6, 2022 when Cantor Fitzgerald changed their price target from $16 to $11 for Anavex Life Sciences Corp.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Anavex Life Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Anavex Life Sciences was filed on December 26, 2024 so you should expect the next rating to be made available sometime around December 26, 2025.

While ratings are subjective and will change, the latest Anavex Life Sciences (AVXL) rating was a maintained with a price target of $40.00 to $42.00. The current price Anavex Life Sciences (AVXL) is trading at is $13.20, which is out of the analyst’s predicted range.